Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
No clinical trials have been registered for Leydig cell hypoplasia due to partial LH resistance.
6 publications have been identified in PubMed for Leydig cell hypoplasia due to partial LH resistance. Research spans Review / Meta-Analysis (67%), Case Report / Case Series (17%), and Clinical Trial Publication (17%).
Wang F (2026). [PMID: 41725111](https://pubmed.ncbi.nlm.nih.gov/41725111/). *Cancer Rep (Hoboken)*. [Case Report / Case Series]
Hubbard L (2025). [PMID: 39243180](https://pubmed.ncbi.nlm.nih.gov/39243180/). *Asian J Androl*. [Review / Meta-Analysis]
Salvio G (2025). [PMID: 39513636](https://pubmed.ncbi.nlm.nih.gov/39513636/). *Asian J Androl*. [Review / Meta-Analysis]
Esteves SC (2025). [PMID: 39800700](https://pubmed.ncbi.nlm.nih.gov/39800700/). *Reprod Biol Endocrinol*. [Review / Meta-Analysis]
Lambert AS (2025). [PMID: 40042209](https://pubmed.ncbi.nlm.nih.gov/40042209/). *Endocr Connect*. [Clinical Trial Publication]
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 7:28 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Leydig cell hypoplasia due to partial LH resistance